Handeln Teijin Limited - 3401 CFD

Teijin Limited, together with its subsidiaries, engages in fibers, films and sheets, composites, healthcare, and IT businesses worldwide. It operates through two segments, Materials Business Field and Healthcare Business Field. The company offers para-aramid, meta-aramid, oxidized PAN, carbon, and polyester fibers; polyethylene naphthalate (PEN) and polyphenylene sulfide resins; polycarbonate resins; flame retardants; polycarbonate films and sheets; polyester and PEN films; automotive composites; plastic glazing products; and LIB separators. It also provides Bonalon and Onealfa for the treatment of osteoporosis; Synvisc, a sodium hyaluronate agent; Loqoa, a transdermal analgesic anti-inflammatory agent; Mucosolvan, an airway mucolytic agent; Alvesco, an inhaled corticosteroid agent for asthma; Feburic, an anti-hyperuricemia; Tricor, an anti-hyperlipidemic agent; Venilon for intravenous immunoglobulin preparation; and Laxoberon laxatives. In addition, the company offers oxygen concentrators for home oxygen therapy; continuous positive airway pressure devices; AutoSet CS, an adaptive servo-ventilator; WalkAide, an electric stimulation device; ReoGo-J, a portable robotic arm that supports the rehabilitation of paralyzed upper limbs; Safhs, a sonic accelerated fracture healing system; VitalLink, a patient information sharing system; orthopedic implantable devices; and functional food ingredients. Further, it offers home healthcare services, as well as produces and rents home healthcare devices. Additionally, the company trades in and sells fiber materials, textiles and apparels, industrial textiles and materials, and films and plastic products; and polyester and recycled polyester fabrics and textiles. It also provides IT services for the healthcare field and enterprises; Web-based enterprise resource planning software package; and e-comics distribution services, as well as engineering solutions. Teijin Limited was founded in 1918 and is headquartered in Tokyo, Japan.